Compass Pathways is trading at $12.22, up 6.50% versus the October 8 close, with no clear company-specific announcement identified to explain the pre-market rise.
- The latest prominent company news surfaced was its October 5 announcement that its second Phase 3 trial achieved its primary endpoint.
- Available evidence does not establish that the October 5 news caused the October 9 move.
- U.S. futures pointed higher, but that broad-market backdrop does not confirm a cause for the stock’s move.